Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer

Clinical Cancer Research

Volumn 6, Issue 3, 2000, Pages 1063-1072

  Van Triest, Baukelien ^a   Pinedo, Herbert M ^a   Blaauwgeers, Johannes L G ^b   Van Diest, Paul J ^a   Schoenmakers, Pascale S ^a   Voorn, Daphne A ^a   Smid, Kees ^a   Hoekman, Klaas ^a   Hoitsma, Henk F W ^b   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; PLATELET DERIVED ENDOTHELIAL CELL GROWTH FACTOR; PROTEIN P53; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; ENZYME ACTIVITY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

AGED; ANTIGENS, CD31; BIOLOGICAL MARKERS; COLORECTAL NEOPLASMS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOKINES; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 12944293119     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Piedbois, P., Buyse, M., Rustum, Y., Machover, D., Erlichman, C., Carlson, R. W., Valone, F., Labianca, R., Doroshow, J. H., and Petrelli, N. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. The Advanced Colorectal Cancer Meta-Analysis Project. J. Clin. Oncol., 10: 896-903, 1992.
2. Moertel, C. G., Fleming, T. R., Macdonald, J. S., Haller, D. G., Laurie, J. A., Goodman, P. J., Ungerleider, J. S., Emerson, W. A., Tormey, D. C., Glick, J. H., Michael, H., Veeder, M. D., and Mailliard, J. A. Fluorouracil plus levamisole for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 332: 352-358, 1990.
3. Haller, D. G. An overview of adjuvant therapy for colorectal cancer. Eur. J. Cancer. 31A: 1255-1263, 1995.
4. Hoover, H. C., Jr., Brandhorst, J. S., Peters, L. C., Surdyke, M. G., Takeshita, V., Madariaga, J., Muenz, L. R., and Hanna, M. G., Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J. Clin. Oncol., 3: 390-399, 1993.
5. Riethmüller, G., Schneider-Gadicke, E., Schlimok, G., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., Pichlmayer, R., Buggisch, P., Witte, J., and the German Cancer Aid 17-7A Study Group. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet, 343: 1177-1183, 1994.
6. Peters, G. J., and Jansen, G. Resistance to antimetabolites. In: R. L. Schilsky, G. A. Milano, and M. J. Ratain (eds.), Principles of Antineoplastic Drug Development and Pharmacology, pp. 543-585. New York: Marcel Dekker, Inc., 1996.
7. Peters, G. J., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., and Pinedo, H. M. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J. Clin. Oncol 12: 2035-2042, 1994.
8. Leichman, C. G., Danenberg, P. V., Tan, M., Metzger, R., Boswell, W., Groshen, S., Baranda, J., Danenberg, K., Leichman, L., and Lenz, H. J. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol., 75: 3223-3229, 1997.
9. Kornmann, M., Danenberg, P. V., Beger, H. G., Danenberg, K. D., Safi, F., Weindel, M., Leder, G. H., Butzer, U., Metzger, R., Pillasch, J., Lenz, H. J., and Link, K. H. Thymidylate synthase is a predictor for response and resistance in hepatic artery infusion chemotherapy. Cancer Lett., 16: 29-35, 1997.
10. Johnston, P. G., Fisher, E. R., Rockette, H. E., Fisher, B., Wolmark, N., Drake, J. C., Chabner, B. A., and Allegra, C. J. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J. Clin. Oncol., 12: 2640-2647, 1994.
11. Friedkin, D., and Roberts, D. The enzymatic synthesis of nucleosides. J. Biol. Chem., 207: 245-256, 1954.
12. Haraguchi, M., Furukawa, R., Sumizawa, T., and Akiyama, S. Sensitivity of human KB cells expressing platelet-derived endothelial cell growth factor to pyrimidine antimetabolites. Cancer Res., 53: 5680-5682, 1993.
13. Patterson, A., Zhang, H., Moghaddam, A., Bicknell, R., Talbot, D., Stratford, I. J., and Harris, A. L. Increased sensitivity to the pro-drug 5′-deoxy-5-fluorouridine and modulation of 5′-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer, 72: 669-675, 1995.
14. Kato, Y., Matsukawa, S., Muraoka, R., and Tanigawa, N. Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. Br. J. Cancer, 75: 506-511, 1997.
15. Schwartz, E. L., Baptiste, N., Megati, S., Wadler, S., and Otter, B. A. 5-Ethoxy-2′-deoxyuridine, a novel substrate for thymidine phosphorylase, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon, an inducer of thymidine phosphorylase expression. Cancer Res., 55: 3543-3550, 1995.
16. Peters, G. J., Laurensse, E., Leyva, A., and Pinedo, H. M. Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicity. Eur. J. Cancer Clin. Oncol., 23: 1869-1881, 1987.
17. Furukawa, T., Yoshimur, A., Sumizawa, T., Haraguchi, M., Akiyama, S., Fukui, K., Ishizawa, M., and Yamada, Y. Angiogenic factor. Nature (Lond.), 356: 668, 1992.
18. Moghaddam, A., and Bicknell, R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry, 31: 12141-12146, 1992.
19. Brown, N. S., and Bicknell, R. Thymidine phosphorylase, 2-deoxy-D-ribose and angiogenesis. Biochem. J., 334: 1-8, 1998.
20. Ishikawa, F., Miyazono, K., Hellman, U., Dexter, H., Wernstedt, C., Hagiwara, K., Usuki, K., Takaku, F., Risau, W., and Heldin, C. H. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature (Lond.), 338: 557-562, 1989.
21. Haraguchi, M., Miyadera, A., Uemura, K., Sumizawa, T., Furukawa, T., Yamada, K., and Akiyama, S-I. Angiogenic activity of enzymes. Nature (Lond.), 368: 198, 1994.
22. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
23. Bossi, P., Viale, G., Lee, A. K. C., Alfana, R. M., Coggi, G., and Bosari, S. Angiogenesis in colorectal tumors: microvessel quantitation in adenomas and carcinomas with clinicopathological correlations. Cancer Res., 55: 5049-5053, 1995.
24. Tanigawa, N., Amaya, H., Matsumura, M., Lu, C., Kitaoka, A., Matsuyama, K., and Muraoka, R. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res., 57: 1043-1046, 1997.
25. Takahashi, Y., Bucana, C. D., Liu, W., Yoneda, J., Kitadai, Y., Cleary, K. R., and Ellis, L. M. Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells. J. Natl. Cancer Inst., 88: 1146-1151, 1996.
26. Takebayashi, Y., Akiyama, S-I., Akiba, S., Yamada, K., Miyadeia, K., Sumizawa, T., Yamada, Y., Murata, F., and Aikou, T. Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma. J. Natl. Cancer Inst., 88: 1110-1117, 1996.
27. Metzger, R., Danenberg, K., Leichman, G. C., Salongo, D., Schwartz, E. L., Wadler, S., Lenz, H-J., Grogher, S., Leichman, L., and Danenberg, P. V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with non-response to 5-fluorouracil. Clin. Cancer Res., 4: 2371-2376, 1998.
28. Reynolds, T. Dutch trial casts doubt on colorectal adjuvant therapy. J. Natl. Cancer Inst., 87: 476-479, 1995.
29. Wagstaff, J. The role of biological response modifiers in the management of patients with colorectal cancer. Eur. J. Cancer, 3IA: 1323-1325, 1995.
30. Peters, G. J., Laurensse, E., Leyva, A., Lankelma, J., and Pinedo, H. M. Sensitivity of human, murine and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res., 46: 20-28, 1986.
31. Bradford, M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
32. Peters, G. J., Van Groeningen, C. J., Laurensse, E., and Pinedo, H. M. Thymidylate synthase from untreated human colorectal cancer and colonie mucosa: enzyme activity and inhibition by 5-fluoro-2′-deoxyuridine-5′-monophosphate. Eur. J. Cancer, 27: 263-267, 1991.
33. Laurensse, E. J., Pinedo, H. M., and Peters, G. J. A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatography. Clin. Chim. Acta, 178: 71-78, 1988.
34. Van der Wilt, C. L., Smid, K., Aherne, G. W., Pinedo, H. M., and Peters, G. J. Evaluation of immunohistochemical staining and activity of thymidylate synthase in cell lines. Adv. Exp. Med. Biol., 338: 605-608, 1993.
35. Fox, S. B., Moghaddam, A., Westwood, M., Turley, H., Bicknell, R., Gatter, K. C., and Harris, A. L. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J. Pathol., 176: 183-190, 1995.
36. Vojtesek, B., Bartek, J., Midgley, C. A., and Lane, D. P. An immunohistochemical analysis of the human nuclear phosphoprotein p53: new monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods, 751: 237-244, 1992.
37. Key, G., Petersen, J. L., Becker, M. H. G., Duchrow, M., Schlueter, C., Askaa, J., and Gerdes, V. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J. Clin. Pathol., 46: 1080-1084, 1993.
38. Parums, D. V., Cordell, J. L., Micklem, K., Heryet, A. R., Gatter, K. C., and Mason, D. Y. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen on routinely processed tissue sections. J. Clin. Pathol., 43: 572-577, 1990.
39. Conn, G., Soderman, D. D., Schaeffer, M. T., Wile, M., Hatcher, V. B., and Thomas, K. A. Purification of a glycoprotein vascular endothelial cell mitogen from a rat glioma-derived cell line. Proc. Natl. Acad. Sci. USA, 87: 1323-1327, 1990.
40. Honkoop, A. H., Pinedo, H. M., De Jong, J. S., Verheul, H. M. W., Linn, S. C., Hoekman, K., Wagstaff, J., and Van Diest, P. J. Effects of chemotherapy on pathologic and biologic characteristics of locally ad-vanced breast cancer. Am. J. Clin. Pathol., 107: 211-218, 1997.
41. Vermeulen, P. B., Gasparini, G., Fox, S. B., Toi, M., Martin, L., McCulloch, P., Pezella, F., Viale, G., Weidner, N., Harris, A. L., and Dirix, L. Y. Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer, 32A: 2474-2484, 1996.
42. Yamachika, T., Nakanishi, H., Inada, K-I., Tsukamoto, T., Kato, T., Fukushima, M., Inoue, M., and Tatematsu, M. A new prognostic factor for colorectal carcinoma, thymidylate synthase, and its therapeutic significance. Cancer (Phila.), 82: 70-77, 1998.
43. Imazono, Y., Takebayashi, Y., Nishiyama, K., Akiba, S., Miyadera, K., Yamada, Y., Akiyama, S-I., and Ohi, Y. Correlation between thymidine phosphorylase expression and prognosis in human renal cell carcinoma. J. Clin. Oncol., 15: 2570-2578, 1997.
44. Koukourakis, M. I., Giatromanolaki, A., O'Byrne, K. J., Comley, M., Whitehouse, R. M., Talbot, D. C., Gatter, K. C., and Harris, A. L. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br. J. Cancer, 75: 477-481, 1997.
45. Fox, S. B., Westwood, M., Moghaddam, A., Comley, M., Turley, H., Whitehouse, R. M., Bicknell, R., Gatter, K. C., and Harris, A. L. The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. Br. J. Cancer, 73: 275-280, 1996.
46. Fox, S. B., Engels, K., Comley, M., Whitehouse, R. M., Turley, H., Gatter, K. C., and Harris, A. L. Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF. Ann. Oncol., 8: 271-275, 1997.
47. Takahashi, Y., Bucana, C. D., Akagi, Y., Liu, W., Cleary, K. R., Mai, M., and Ellis, L. M. Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer. Clin. Cancer Res., 4: 429-434, 1998.
48. Saeki, T., Takashima, S., Hosokawa, S., Moriwake, S., Nagasako, K., Masaki, T., Salomon, D. S., and Ishitsuka, H. Differential expression of platelet-derived endothelial cell growth factor (thymidine phosphorylase) in nonpolyploid and polyploid lesions of the colon. Int. J. Oncol., 8: 1105-1111, 1996.
49. Kieser, A., Weich, H. A., Brandner, G., Marme, D., and Kolch, W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene, 9: 963-969, 1994.
50. Dameron, K. M., Volpert, O. V., Tainsky, M. A., and Bouck, N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science (Washington DC), 265: 1582-1584, 1994.
51. Vermeulen, P. B., Verhoeven, D., Hubens, G., Van Marck, E., Goovaerts, G., Huyghe, M., De Bruijn, E. A., Van Oosterom, A. T., and Dirix, L. Y. Microvessel density, endothelial cell proliferation and tumour cell proliferation in human colorectal adenocarcinomas. Ann. Oncol., 6: 59-64, 1995.
52. Eda, H., Fujimoto, K., Watanabe, S-I., Ura, M., Hino, A., Tanaka, Y., Wada, K., and Ishitsuka, H. Cytokines induce thymidine phosphorylase expression in tumor cells and make them more susceptible to 5′-deoxy-5-fluorouridine. Cancer Chemother. Pharmacol., 32: 333-338, 1993.